HDAC3 and Charcot-Marie-Tooth disease type 1A: The aim of this study was to determine whether inhibition of HDAC3 enzymatic function using the HDAC3 inhibitor (HDAC3i) RGFP966 could be a therapeutic approach in a CMT1A mouse model.